We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Serena
Dhir
+44 (0) 121 415 8445
vitdalize@trials.bham.ac.uk
Dr
Dhruv
Parekh
-
d.parekh@bham.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Vitamin D deficiency
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Vitamin D deficiency (low vitamin D levels) is common in patients who are unwell (around 70%). This has been found to be related to an increased risk of infection and death. There are many reasons why patients are poorly and those who do survive can suffer long-term health problems in the future. It is not known whether being vitamin D deficient is a cause or effect of being unwell, and research into whether vitamin D is useful is not clear. There are no guidelines to measure and treat patients admitted to intensive care who are critically ill and are vitamin D deficient. Vitamin D is cheap and easily available, and if using vitamin D is found to help, can be quickly put into standard practice in hospitals. VITDALIZE is an international trial that aims to recruit 2400 patients from across Europe. Countries that are participating include the UK, Austria, Germany and Belgium. The UK part of VITDALIZE aims to recruit 600 patients into the trial. The aim of this trial is to see if giving a high dose of vitamin D in critically ill patients can improve survival, length of hospital stay, and quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2019 Protocol article in https://pubmed.ncbi.nlm.nih.gov/31722941/ (added 15/01/2025)
You can take part if:
You may not be able to take part if:
1. Severe gastrointestinal dysfunction (>400 ml nasogastric tube residual volume)/unable to receive trial medication2. Not expected to survive initial 48 hours of admission or treatment withdrawal imminent within 24 hours3. Patient with DNAR (Do Not Attempt Resuscitation) orders in place4. Hypercalcemia (>2.65 mmol/l corrected calcium and/or >1.35 mmol/l ionized calcium at screening)5. Known kidney stones within the last 12 months6. Known active tuberculosis within the last 12 months7. Known sarcoidosis within the last 12 months8. Women of childbearing age who have tested positive for pregnancy or who are lactating9. Known hypersensitivity to the trial drug or excipient10. Medical team deem it not suitable to include patient11. Known prisoners in the custody of HM Prison and Probation services
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Serena
Dhir
+44 (0) 121 415 8445
vitdalize@trials.bham.ac.uk
Dr
Dhruv
Parekh
-
d.parekh@bham.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Medical University of Graz and funded by Health Technology Assessment Programme; Grant Codes: 17/147/33.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 46276
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
